KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Receivables - Net (2017 - 2025)

Historic Receivables - Net for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $1.4 billion.

  • Amneal Pharmaceuticals' Receivables - Net rose 1905.48% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 1905.48%. This contributed to the annual value of $775.7 million for FY2024, which is 3535.47% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Receivables - Net stood at $1.4 billion for Q3 2025, which was up 1905.48% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Receivables - Net peaked at $1.4 billion during Q3 2025, and registered a low of $530.6 million during Q1 2021.
  • Over the past 5 years, Amneal Pharmaceuticals' median Receivables - Net value was $1.2 billion (recorded in 2024), while the average stood at $1.1 billion.
  • In the last 5 years, Amneal Pharmaceuticals' Receivables - Net tumbled by 6308.45% in 2021 and then soared by 8982.58% in 2023.
  • Amneal Pharmaceuticals' Receivables - Net (Quarter) stood at $662.6 million in 2021, then rose by 11.95% to $741.8 million in 2022, then surged by 61.77% to $1.2 billion in 2023, then increased by 8.65% to $1.3 billion in 2024, then increased by 10.8% to $1.4 billion in 2025.
  • Its Receivables - Net was $1.4 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.3 billion in Q1 2025.